Equities analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to report earnings of $0.20 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for LeMaitre Vascular’s earnings. The highest EPS estimate is $0.24 and the lowest is $0.18. LeMaitre Vascular reported earnings of $0.21 per share during the same quarter last year, which indicates a negative year over year growth rate of 4.8%. The firm is scheduled to report its next quarterly earnings results on Wednesday, February 20th.

According to Zacks, analysts expect that LeMaitre Vascular will report full-year earnings of $1.03 per share for the current fiscal year, with EPS estimates ranging from $1.02 to $1.06. For the next year, analysts expect that the firm will post earnings of $0.94 per share, with EPS estimates ranging from $0.88 to $0.99. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.21. The company had revenue of $24.17 million for the quarter, compared to analyst estimates of $26.06 million. LeMaitre Vascular had a net margin of 21.09% and a return on equity of 19.49%.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Wednesday, September 26th. Roth Capital downgraded shares of LeMaitre Vascular from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $38.00 to $39.00 in a research note on Tuesday, October 2nd. ValuEngine downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, June 21st. BidaskClub downgraded shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Canaccord Genuity boosted their price target on shares of LeMaitre Vascular from $31.00 to $35.00 and gave the stock a “hold” rating in a research note on Monday, July 9th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $35.63.

In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 39,820 shares of the company’s stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $37.34, for a total value of $1,486,878.80. Following the completion of the sale, the chairman now owns 3,085,291 shares of the company’s stock, valued at $115,204,765.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David B. Roberts sold 21,005 shares of the company’s stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $35.72, for a total transaction of $750,298.60. Following the completion of the sale, the director now directly owns 5,373 shares of the company’s stock, valued at approximately $191,923.56. The disclosure for this sale can be found here. Insiders sold 97,506 shares of company stock valued at $3,608,759 in the last ninety days. Insiders own 20.30% of the company’s stock.

Large investors have recently modified their holdings of the business. Piedmont Investment Advisors LLC bought a new stake in LeMaitre Vascular in the second quarter valued at approximately $119,000. Tower Research Capital LLC TRC increased its stake in LeMaitre Vascular by 222.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,451 shares of the medical instruments supplier’s stock valued at $149,000 after purchasing an additional 3,072 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in LeMaitre Vascular in the first quarter valued at approximately $215,000. Jane Street Group LLC bought a new stake in LeMaitre Vascular in the second quarter valued at approximately $206,000. Finally, Creative Planning bought a new stake in LeMaitre Vascular in the second quarter valued at approximately $220,000. 79.75% of the stock is owned by hedge funds and other institutional investors.

Shares of LMAT traded up $0.29 on Friday, reaching $28.22. 222,174 shares of the company’s stock were exchanged, compared to its average volume of 151,980. The company has a market cap of $748.16 million, a price-to-earnings ratio of 32.81, a price-to-earnings-growth ratio of 2.42 and a beta of 0.63. LeMaitre Vascular has a 12 month low of $26.45 and a 12 month high of $41.28.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 6th. Investors of record on Tuesday, November 20th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date of this dividend is Monday, November 19th. LeMaitre Vascular’s dividend payout ratio (DPR) is 32.56%.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Further Reading: Understanding Stock Ratings

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.